Close Menu

glioblastoma

Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.

Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.

One cohort will involve NSCLC patients with MET exon 14 skipping mutations, while two other cohorts will enroll patients with solid tumors with MET amplifications and fusions.

The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.

The first-in-class VT1021 would treat patients with various cancers whose tumors have high CD36 expression by reprogramming the tumor immune microenvironment.

The trial will evaluate the effects of the single agent ONC201 in patients who have recurrent high-grade gliomas with low EGFR expression.

The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.

The Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) clinical trial is enrolling its first patients.

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.

The firm will use the proceeds to further a validation study  tracking the ability of its cell culture assay to predict patient response to cancer therapies.

Pages